The analysis of the gene-targeting frequency by CIS statistics (Methods) showed that among the most targeted genes by LV insertions in the CsA treatment group were KDM2A, RERE, TNRC6C, TNRC6C, PACS1, and NSD1 (Fig. 2D). The gene discussed is NSD1; the disease is in situ carcinoma.